Research and Reports on Genetics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Rapid Communication - Research and Reports on Genetics (2024) Volume 6, Issue 5

The Impact of Genetic Variation on Drug Response: Toward a New Era of Pharmacogenomics

Scott Xu*

Department of Pathology, Stanford University, Stanford, USA

*Corresponding Author:
Scott Xu
Department of Pathology
Stanford University, Stanford, USA
E-mail: xuscott@cjlu.edu.cn

Received: 02-Sep-2024, Manuscript No. AARRGS-24- 148041; Editor assigned: 05-Sep-2024, Pre QC No. AARRGS-24- 148041(PQ); Reviewed: 19-Sep-2024, QC No. AARRGS-24-148041; Revised: 23-Sep-2024, Manuscript No. AARRGS-24- 148041 (R); Published: 30-Sep-2024, DOI:10.35841/aarrgs-6.5.227

Citation: Xu S. The impact of genetic variation on drug response: Toward a new era of pharmacogenomics.J Res Rep Genet.2024;6(5):227

Visit for more related articles at Research and Reports on Genetics

Introduction

In the era of modern medicine, the concept of "one size fits all" is quickly becoming outdated, particularly when it comes to drug therapies. Individual responses to medications vary widely, and much of this variation can be traced to genetic differences. Pharmacogenomics, the study of how genes influence drug response, is at the forefront of precision medicine, aiming to tailor drug therapies to each patient's unique genetic makeup. As researchers continue to uncover the genetic underpinnings of drug metabolism, efficacy, and adverse reactions, pharmacogenomics is opening new doors for personalized healthcare [1].

Genetic Variation and Drug Metabolism

One of the core areas where genetic variation plays a crucial role is in drug metabolism. The Cytochrome P450 (CYP) enzymes, which are responsible for metabolizing around 70–80% of all clinically used drugs, are influenced by genetic differences. Specific variants in the genes encoding these enzymes can alter the speed at which a drug is metabolized. For instance, individuals with certain variants of the CYP2D6 gene may metabolize drugs too slowly (poor metabolizers) or too quickly (ultra-rapid metabolizers), leading to either drug toxicity or a lack of therapeutic effect [2, 3].

A common example of this variation can be seen in patients prescribed codeine. Codeine is metabolized into morphine by the enzyme CYP2D6. In poor metabolizers, this process occurs slowly, leading to inadequate pain relief, while ultrarapid metabolizers convert codeine into morphine quickly, increasing the risk of morphine toxicity. Pharmacogenomic testing allows clinicians to identify these genetic variations and adjust medication regimens accordingly, avoiding adverse effects and improving efficacy [4].

Impact of Genetic Variation on Drug Efficacy

Beyond metabolism, genetic variation can influence how effective a drug is in treating a condition. This is particularly evident in the field of oncology, where targeted therapies have transformed treatment for many cancers. For instance, patients with mutations in the EGFR gene often respond favorably to EGFR inhibitors, which block the signaling pathways that promote cancer growth in these individuals. Similarly, patients with mutations in the KRAS gene typically do not respond to the same therapies, requiring alternative treatment strategies. Pharmacogenomics also plays a significant role in managing chronic conditions. For example, the anticoagulant warfarin is used to prevent blood clots, but its optimal dosage varies significantly among patients. Variants in the CYP2C9 and VKORC1 genes affect both the metabolism of warfarin and a patient’s sensitivity to the drug. By identifying these genetic variants through testing, clinicians can more accurately prescribe the appropriate warfarin dose, reducing the risk of bleeding or clotting complications [5, 6].

Genetic Variation and Adverse Drug Reactions (ADRs)

Adverse Drug Reactions (ADRs) are a major cause of hospitalization and even death. Genetic variation is a key factor that predisposes some individuals to ADRs, making pharmacogenomics an essential tool for predicting and preventing these reactions. One well-known example is the risk of hypersensitivity to the antiretroviral drug abacavir, used in HIV treatment. Individuals with the HLA-B5701 allele are at a significantly higher risk of severe hypersensitivity reactions. Screening for this allele before starting treatment has become a standard practice, significantly reducing the risk of ADRs [7].

Similarly, patients of Asian descent who carry the HLA-B1502 allele are at higher risk of developing severe skin reactions, such as Stevens-Johnson syndrome, when treated with the anticonvulsant drug carbamazepine. Genetic testing for HLA-B1502 helps clinicians avoid using carbamazepine in at-risk patients, preventing life-threatening reactions [8].

Pharmacogenomics in Clinical Practice

Pharmacogenomics is becoming a cornerstone of precision medicine, where treatments are designed around an individual’s genetic profile. Genetic testing for drug response is already being used in areas such as oncology, cardiology, psychiatry, and infectious diseases. By integrating genetic data into clinical decision-making, physicians can reduce the trialand- error process of finding the right drug and dose, leading to more effective and safer treatments. However, while the benefits of pharmacogenomics are clear, several challenges remain. Wider access to genetic testing is needed, as well as further education for healthcare providers on interpreting pharmacogenomic results. Additionally, more research is required to expand the number of genetic markers associated with drug response, especially for commonly prescribed medications [9].

Ethical and Social Considerations

The implementation of pharmacogenomics also raises important ethical and social considerations. Genetic privacy and the potential for genetic discrimination in employment or insurance are critical concerns. Additionally, disparities in access to pharmacogenomic testing, particularly in low-resource settings, need to be addressed to ensure that the benefits of personalized medicine are available to all populations. Informed consent and patient education about the implications of pharmacogenomic testing are essential. Patients should understand how their genetic information will be used, stored, and protected. Clear guidelines and policies must be in place to safeguard against misuse of genetic data [10].

Conclusion

The impact of genetic variation on drug response has opened the door to a new era of pharmacogenomics, where personalized medicine is no longer a distant dream but an evolving reality. As genetic testing becomes more integrated into healthcare, pharmacogenomics has the potential to improve drug efficacy, reduce adverse drug reactions, and optimize dosing, ultimately transforming patient care. However, realizing the full potential of pharmacogenomics requires addressing challenges such as access to testing, education for clinicians, and ethical concerns surrounding genetic privacy. As these issues are navigated, pharmacogenomics will continue to advance, bringing us closer to the goal of precision medicine for all. The future of medicine lies in tailoring therapies to each patient’s genetic makeup, offering more effective and safer treatments, and improving health outcomes on a global scale.

References

  1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279:1200–1205.

    2. Indexed at, Google Scholar, Cross Ref

  2. Sadée W. Genomics and drugs: finding the optimal drug for the right patient. Pharm Res. 1998;15:959–963.

    3. Indexed at, Google Scholar, Cross Ref

  3. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960;2:485–490.

    4. Indexed at, Google Scholar, Cross Ref

  4. Vatsis KP, Martell KJ, Weber WW. Diverse point mutations in the human gene for polymorphic N-acetyltransferase. Proc Natl Acad Sci U S A. 1991;88:6333.

    5. Indexed at, Google Scholar, Cross Ref

  5. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980;32:651–62.

    6. Indexed at, Google Scholar

  6. Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet. 1996;58:694–702.

    7. Indexed at, Google Scholar

  7. Tanaka E, Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J Clin Pharm Ther. 1999;24:7–16.

    8. Indexed at, Google Scholar, Cross Ref

  8. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998;281:1820–1821.

    9. Indexed at, Google Scholar, Cross Ref

  9. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487–491.

    10. Indexed at, Google Scholar, Cross Ref

  10. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.

    11. Indexed at, Google Scholar, Cross Ref

Get the App